Unassociated Document

0001140361-13-028384.txt : 20130718 0001140361-13-028384.hdr.sgml : 20130718 20130718174753 ACCESSION NUMBER: 0001140361-13-028384 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20130716 FILED AS OF DATE: 20130718 DATE AS OF CHANGE: 20130718 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Landy Joseph P. CENTRAL INDEX KEY: 0001220638 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975539 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER NAME: FORMER CONFORMED NAME: LANDY JOSEPH DATE OF NAME CHANGE: 20030225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAYE CHARLES R CENTRAL INDEX KEY: 0001239318 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975540 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Warburg Pincus X LLC CENTRAL INDEX KEY: 0001414564 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975543 BUSINESS ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-878-0600 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Warburg Pincus X, L.P. CENTRAL INDEX KEY: 0001414561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975544 BUSINESS ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-878-0600 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Warburg Pincus Private Equity X, L.P. CENTRAL INDEX KEY: 0001414565 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975546 BUSINESS ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-878-0600 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WARBURG PINCUS & CO. CENTRAL INDEX KEY: 0000929408 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975547 BUSINESS ADDRESS: STREET 1: 450 LEXINGTON AVENUE STREET 2: NEW YORK CITY: NY STATE: NY ZIP: 100173147 BUSINESS PHONE: 2128780600 MAIL ADDRESS: STREET 1: 450 LEXINGTON AVENUE STREET 2: NEW YORK CITY: NY STATE: NY ZIP: 100173147 FORMER NAME: FORMER CONFORMED NAME: WARBURG PINCUS & CO DATE OF NAME CHANGE: 19940901 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WARBURG PINCUS LLC CENTRAL INDEX KEY: 0001162870 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975541 BUSINESS ADDRESS: STREET 1: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-878-0600 MAIL ADDRESS: STREET 1: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Warburg Pincus X Partners, L.P. CENTRAL INDEX KEY: 0001451560 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975545 BUSINESS ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-878-0600 MAIL ADDRESS: STREET 1: C/O WARBURG PINCUS LLC STREET 2: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER NAME: FORMER CONFORMED NAME: WARBURG PINCUS X PARTNERS, L.P. DATE OF NAME CHANGE: 20081208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Warburg Pincus Partners LLC CENTRAL INDEX KEY: 0001322709 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32626 FILM NUMBER: 13975542 BUSINESS ADDRESS: STREET 1: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-878-0600 MAIL ADDRESS: STREET 1: 450 LEXINGTON AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Talon Therapeutics, Inc. CENTRAL INDEX KEY: 0001140028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320064979 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2207 BRIDGEPOINTE PARKWAY STREET 2: SUITE 250 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: 650-588-6404 MAIL ADDRESS: STREET 1: 2207 BRIDGEPOINTE PARKWAY STREET 2: SUITE 250 CITY: SAN MATEO STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: Hana Biosciences Inc DATE OF NAME CHANGE: 20041006 FORMER COMPANY: FORMER CONFORMED NAME: EMAIL REAL ESTATE COM INC DATE OF NAME CHANGE: 20010504 4 1 doc1.xml FORM 4 X0306 4 2013-07-16 1 0001140028 Talon Therapeutics, Inc. TLON 0000929408 WARBURG PINCUS & CO. 450 LEXINGTON AVENUE NEW YORK NY 10017 1 0 1 0 0001414565 Warburg Pincus Private Equity X, L.P. C/O WARBURG PINCUS & CO. 450 LEXINGTON AVENUE NEW YORK NY 10017 1 0 1 0 0001451560 Warburg Pincus X Partners, L.P. C/O WARBURG PINCUS & CO. 450 LEXINGTON AVENUE NEW YORK NY 10017 1 0 1 0 0001414561 Warburg Pincus X, L.P. C/O WARBURG PINCUS & CO. 450 LEXINGTON AVENUE NEW YORK NY 10017 1 0 1 0 0001414564 Warburg Pincus X LLC C/O WARBURG PINCUS & CO. 450 LEXINGTON AVENUE NEW YORK NY 10017 1 0 1 0 0001322709 Warburg Pincus Partners LLC C/O WARBURG PINCUS & CO. 450 LEXINGTON AVENUE NEW YORK NY 10017 1 0 1 0 0001162870 WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001239318 KAYE CHARLES R C/O WARBURG PINCUS & CO. 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 0001220638 Landy Joseph P. C/O WARBURG PINCUS & CO. 450 LEXINGTON AVENUE NEW YORK NY 10017 0 0 1 0 Common Stock, $0.001 Par Value ("Common Stock") 2013-07-16 4 C 0 65016890 .736 A 65016890 I See footnotes Common Stock 2013-07-16 4 C 0 37775503 0.30 A 102792393 I See footnotes Common Stock 2013-07-16 4 C 0 49537551 0.350 A 152329944 I See footnotes Common Stock 2013-07-16 4 S 0 152329944 0.056 D 0 I See footnotes Series A-1 Convertible Preferred Stock, $0.001 Par Value 0.736 2013-07-16 4 C 0 360000 100 D 2010-06-07 Common Stock 63037004 0 I See footnotes Series A-1 Preferred Stock 0.736 2013-07-16 4 C 0 11307 100 D 2010-09-10 Common Stock 1979886 0 I See footnotes Series A-2 Convertible Preferred Stock, $0.001 Par Value 0.30 2013-07-16 4 C 0 99000 100 D 2012-01-09 Common Stock 37775503 0 I See footnotes Series A-3 Convertible Preferred Stock, $0.001 Par Value 0.35 2013-07-16 4 C 0 27000 100 D 2012-07-03 Common Stock 8460526 0 I See footnotes Series A-3 Preferred Stock 0.35 2013-07-16 4 C 0 54000 100 D 2012-08-17 Common Stock 16737865 0 I See footnotes Series A-3 Preferred Stock 0.35 2013-07-16 4 C 0 27000 100 D 2012-11-14 Common Stock 8189762 0 I See footnotes Series A-3 Preferred Stock 0.35 2013-07-16 4 C 0 54000 100 D 2013-01-11 Common Stock 16149398 0 I See footnotes Right to Acquire Series A-3 Convertible Preferred Stock 100 2013-07-16 4 J 0 420000 D 2012-01-09 Series A-3 Convertible Preferred Stock 420000 0 I See footnotes See Exhibit 99.1; Note 1. See Exhibit 99.1; Note 2. See Exhibit 99.1; Note 3. See Exhibit 99.1; Note 4. See Exhibit 99.1; Note 5. Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signatures ***The Power of Attorney given by Warburg Pincus & Co. was previously filed with the U.S. Securities & Exchange Commission on January 15, 2013 as an exhibit to a statement on Schedule 13D/A filed by Warburg Pincus Private Equity X, L.P. with respect to Talon Therapeutics, Inc. and is hereby incorporated by reference. Warburg Pincus & Co., /s/ Scott A. Arenare, Attorney-in-Fact*** 2013-07-18 EX-99.1 2 misc1.htm MISCELLANEOUS EXHIBITS Unassociated Document

Designated Filer:	Warburg Pincus & Co.
Issuer & Ticker Symbol:	Talon Therapeutics, Inc. [TLON]
Date of Event Requiring Statement:	July 16, 2013

Explanation of Responses:

(1) This Form 4 is filed on behalf of Warburg Pincus Private Equity X, L.P., a Delaware limited partnership (“WP X”), Warburg Pincus X Partners, L.P., a Delaware limited partnership (“WPP X” and, together with WP X, the “WP X Funds”), Warburg Pincus X, L.P., a Delaware limited partnership and the sole general partner of each of the WP X Funds (“WP X LP”), Warburg Pincus X LLC, a Delaware limited liability company and the sole general partner of WP X LP (“WP X LLC”), Warburg Pincus Partners LLC, a New York limited liability company and the sole member of WP X LLC (“WPP LLC”), Warburg Pincus & Co., a New York general partnership and the managing member of WPP LLC (“WP”), Warburg Pincus LLC, a New York limited liability company that manages each of the WP X Funds (“WP LLC”), and Charles R. Kaye and Joseph P. Landy, each a Managing General Partner of WP and a Co-President and Managing Member of WP LLC. Messrs. Kaye and Landy may be deemed to control the WP X Funds, WP X LP, WP X LLC, WPP LLC, WP and WP LLC. Each of the WP X Funds, WP X LP, WP X LLC, WPP LLC, WP, WP LLC, and Messrs. Charles R. Kaye and Joseph P. Landy is a “Warburg Pincus Reporting Person” and collectively, the “Warburg Pincus Reporting Persons.” This Form 4 shall not be deemed an admission that any Warburg Pincus Reporting Person, other than the WP X Funds, or any other person referred to herein is or was a beneficial owner of any Securities (as defined below) or has or had the right to acquire Series A-3 Preferred for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose or that any Reporting Person or other person has an obligation to file this Form 4. The WP X Funds, WP X LP, WP X LLC, WPP LLC and WP are directors-by-deputization solely for purposes of Section 16 of the Exchange Act.

(2) Prior to the Conversion (defined below), WP X directly beneficially owned (i) 359,797 shares of Series A-1 Convertible Preferred Stock, par value $0.001 per share (the “Series A-1 Preferred”), of Talon Therapeutics, Inc., a Delaware corporation (the “Company”), (ii) 95,931 shares of Series A-2 Convertible Preferred Stock, par value $0.001 per share (the “Series A-2 Preferred”), of the Company and (iii) 156,978 shares of Series A-3 Convertible Preferred Stock, par value $0.001 per share (the “Series A-3 Preferred”), of the Company and WPP X directly beneficially owned (i) 11,510 shares of Series A-1 Preferred, (ii) 3,069 shares of Series A-2 Preferred, and (iii) 5,022 shares of Series A-3 Preferred. On July 16, 2013, the Series A-1 Preferred held by the WP X Funds was converted into 65,016,890 shares of common stock, par value $0.001 per share (the “Common Stock”), the Series A-2 Preferred held by the WP X Funds was converted into 37,775,503 shares of Common Stock and the Series A-3 Preferred Stock held by the WP X Funds was converted into 49,537,551 shares of Common Stock (such conversions are referred to herein as the “Conversion” and the converted shares of Common Stock, collectively with the Series A-1 Preferred, the Series A-2 Preferred and the Series A-3 Preferred, are referred to herein as the “Securities”). By reason of the provisions of Rule 16a-1 of the Exchange Act, each of the Warburg Pincus Reporting Persons, other than the WP X Funds, may be deemed to be the beneficial owners of an indeterminate portion of the Securities that may be deemed to be beneficially owned by the WP X Funds, and each WP X Fund may be deemed to beneficially own an indeterminate portion of the Securities that may be deemed to be beneficially owned by the other WP X Fund. Each of the Warburg Pincus Reporting Persons, other than the WP X Funds, may be deemed to have an indirect pecuniary interest in an indeterminate portion of the Securities that may be deemed to be beneficially owned by the WP X Funds. Each Warburg Pincus Reporting Person disclaims beneficial ownership of all Securities that may be deemed to be beneficially owned by the WP X Funds, except to the extent of any indirect pecuniary interest therein, and each WP X Fund disclaims beneficial ownership of all Securities that may be deemed to be beneficially owned by the other WP X Fund.

(3) Each share of (i) Series A-1 Preferred converted into such number of shares of Common Stock, equal to the accreted value of such share of Series A-1 Preferred as of July 16, 2013, divided by a conversion price equal to $0.736, (ii) Series A-2 Preferred converted into such number of shares of Common Stock, equal to the accreted value of such share of Series A-2 Preferred as of July 16, 2013, divided by a conversion price equal to $0.30, and (iii) Series A-3 Preferred converted into such number of shares of

Designated Filer:	Warburg Pincus & Co.
Issuer & Ticker Symbol:	Talon Therapeutics, Inc. [TLON]
Date of Event Requiring Statement:	July 16, 2013

Common Stock, equal to the accreted value of such share of Series A-3 Preferred as of July 16, 2013, divided by a conversion price equal to $0.35. Unless converted or redeemed, the Series A-1 Preferred, Series A-2 Preferred and Series A-3 Preferred do not expire.

(4) Pursuant to the Securities Purchase Agreement, dated as of July 16, 2013 (the “Securities Purchase Agreement”), by and among WP X, WPP X, Spectrum Pharmaceuticals, Inc., Eagle Acquisition Merger Sub, Inc. and the other parties listed therein, WP X and WPP X sold in the aggregate 152,329,944 shares of Common Stock to Eagle Acquisition Merger Sub, Inc. for an aggregate purchase price of $8,544,815 (representing a per-Common Share price of approximately $0.056) and certain contingent value rights representing the right to receive a pro rata portion of contingent cash payments upon the achievement of certain milestones.

(5) WP X and WPP X ceased to have the contractual right to acquire up to 420,000 additional shares of Series A-3 Preferred for $100 per share pursuant to the terms of Investment Agreement, dated as of January 9, 2012 (the “Investment Agreement”), by and among WP X, WPPX and the Company as a result of the termination of the Investment Agreement on July 16, 2013. By reason of the provisions of Rule 16a-1 of the Exchange Act, each of the Warburg Pincus Reporting Persons, other than the WP X Funds, may be deemed to be the beneficial owners of an indeterminate portion of such right to acquire shares of Series A-3 Preferred that may be deemed to be beneficially owned by the WP X Funds, and each WP X Fund may be deemed to beneficially own an indeterminate portion of the right to acquire shares of Series A-3 Preferred that may be deemed to be beneficially owned by the other WP X Fund. Each of the Warburg Pincus Reporting Persons, other than the WP X Funds, may be deemed to have an indirect pecuniary interest in an indeterminate portion of the right to acquire shares of Series A-3 Preferred that may be deemed to be beneficially owned by the WP X Funds. Each Warburg Pincus Reporting Person disclaims beneficial ownership of the right to acquire shares of Series A-3 Preferred that may be deemed to be beneficially owned by the WP X Funds, except to the extent of any indirect pecuniary interest therein, and each WP X Fund disclaims beneficial ownership of right to acquire shares of Series A-3 Preferred that may be deemed to be beneficially owned by the other WP X Fund.

EX-99.2 3 misc2.htm MISCELLANEOUS EXHIBITS Unassociated Document

Designated Filer:	Warburg Pincus & Co.
Issuer & Ticker Symbol:	Talon Therapeutics, Inc. [TLON]
Date of Event Requiring Statement:	July 16, 2013

Joint Filer Information

Joint Filers:

1.	Name:	Warburg Pincus Private Equity X, L.P.
	Address:	C/O WARBURG PINCUS & CO.
		450 LEXINGTON AVENUE
		New York, NY 10017

2.	Name:	Warburg Pincus X Partners, L.P.
	Address:	C/O WARBURG PINCUS & CO.
		450 LEXINGTON AVENUE
		New York, NY 10017

3.	Name:	Warburg Pincus X, L.P.
	Address:	C/O WARBURG PINCUS & CO.
		450 LEXINGTON AVENUE
		New York, NY 10017

4.	Name:	Warburg Pincus X LLC
	Address:	C/O WARBURG PINCUS & CO.
		450 LEXINGTON AVENUE
		New York, NY 10017

5.	Name:	Warburg Pincus Partners LLC
	Address:	C/O WARBURG PINCUS & CO.
		450 LEXINGTON AVENUE
		New York, NY 10017

6.	Name:	Warburg Pincus LLC
	Address:	450 LEXINGTON AVENUE
		New York, NY 10017

7.	Name:	Warburg Pincus & Co.
	Address:	450 LEXINGTON AVENUE
		New York, NY 10017

8.	Name:	Charles R. Kaye
	Address:	C/O WARBURG PINCUS & CO.
		450 LEXINGTON AVENUE
		New York, NY 10017

9.	Name:	Joseph P. Landy
	Address:	C/O WARBURG PINCUS & CO.
		450 LEXINGTON AVENUE
		New York, NY 10017

EX-99.3 4 misc3.htm MISCELLANEOUS EXHIBITS Unassociated Document

Designated Filer:	Warburg Pincus & Co.
Issuer & Ticker Symbol:	Talon Therapeutics, Inc. [TLON]
Date of Event Requiring Statement:	July 16, 2013

Joint Filers’ Signatures

WARBURG PINCUS PRIVATE EQUITY X, L.P.
By: Warburg Pincus X, L.P., its General Partner,
	By: Warburg Pincus X LLC, its General Partner,
		By: Warburg Pincus Partners LLC, its Sole Member,
			By: Warburg Pincus & Co., its Managing Member


By: /s/ Scott A. Arenare				Date: July 18, 2013
	Name: Scott A. Arenare
	Title: Attorney-in-Fact*


WARBURG PINCUS X PARTNERS, L.P.
By: Warburg Pincus X, L.P., its General Partner,
	By: Warburg Pincus X LLC, its General Partner,
		By: Warburg Pincus Partners LLC, its Sole Member,
			By: Warburg Pincus & Co., its Managing Member


By: /s/ Scott A. Arenare				Date: July 18, 2013
	Name: Scott A. Arenare
	Title: Attorney-in-Fact*


WARBURG PINCUS X, L.P.
By: Warburg Pincus X LLC, its General Partner,
	By: Warburg Pincus Partners LLC, its Sole Member,
		By: Warburg Pincus & Co., its Managing Member


By: /s/ Scott A. Arenare				Date: July 18, 2013
	Name: Scott A. Arenare
	Title: Attorney-in-Fact*


WARBURG PINCUS X LLC
By: Warburg Pincus Partners LLC, its Sole Member,
	By: Warburg Pincus & Co., its Managing Member


By: /s/ Scott A. Arenare				Date: July 18, 2013
	Name: Scott A. Arenare
	Title: Attorney-in-Fact*


WARBURG PINCUS PARTNERS LLC
By: Warburg Pincus & Co., its Managing Member


By: /s/ Scott A. Arenare				Date: July 18, 2013
	Name: Scott A. Arenare
	Title: Attorney-in-Fact*

Designated Filer:	Warburg Pincus & Co.
Issuer & Ticker Symbol:	Talon Therapeutics, Inc. [TLON]
Date of Event Requiring Statement:	July 16, 2013

Joint Filers’ Signatures (cont’d)

WARBURG PINCUS & CO.


By: /s/ Scott A. Arenare		Date: July 18, 2013
	Name: Scott A. Arenare
	Title: Attorney-in-Fact*


WARBURG PINCUS LLC


By: /s/ Scott A. Arenare		Date: July 18, 2013
	Name: Scott A. Arenare
	Title: Managing Director


CHARLES R. KAYE


By: /s/ Scott A. Arenare		Date: July 18, 2013
	Name: Charles R. Kaye
	By: Scott A. Arenare, Attorney-in-Fact*


JOSEPH P. LANDY


By: /s/ Scott A. Arenare		Date: July 18, 2013
	Name: Joseph P. Landy
	By: Scott A. Arenare, Attorney-in-Fact*

The Power of Attorney given by each of Warburg Pincus & Co., Mr. Kaye and Mr. Landy was filed with the U.S. Securities & Exchange Commission on January 15, 2013 as an exhibit to a statement on Schedule 13D/A filed by Warburg Pincus Private Equity X, L.P. with respect to Talon Therapeutics, Inc. and is hereby incorporated by reference.